vs
Amneal Pharmaceuticals, Inc.（AMRX）与越洋钻探（RIG）财务数据对比。点击上方公司名可切换其他公司
越洋钻探的季度营收约是Amneal Pharmaceuticals, Inc.的1.3倍（$1.0B vs $814.3M），Amneal Pharmaceuticals, Inc.净利率更高（4.3% vs 2.4%，领先1.9%），Amneal Pharmaceuticals, Inc.同比增速更快（11.5% vs 9.6%），越洋钻探自由现金流更多（$321.0M vs $108.5M），过去两年越洋钻探的营收复合增速更高（16.9% vs 11.1%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
越洋钻探（Transocean Ltd.）是按营收计全球规模最大的海上钻探承包商，总部位于瑞士施泰因豪森，起源于美国，目前在加拿大、美国、挪威、英国、印度、巴西、新加坡等20个国家设有办事机构，业务覆盖全球主要海上油气开采区域。
AMRX vs RIG — 直观对比
营收规模更大
RIG
是对方的1.3倍
$814.3M
营收增速更快
AMRX
高出1.9%
9.6%
净利率更高
AMRX
高出1.9%
2.4%
自由现金流更多
RIG
多$212.5M
$108.5M
两年增速更快
RIG
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $1.0B |
| 净利润 | $35.1M | $25.0M |
| 毛利率 | 36.5% | 42.0% |
| 营业利润率 | 13.8% | 23.0% |
| 净利率 | 4.3% | 2.4% |
| 营收同比 | 11.5% | 9.6% |
| 净利润同比 | 212.9% | 257.1% |
| 每股收益（稀释后） | $0.10 | $0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRIG
| Q4 25 | $814.3M | $1.0B | ||
| Q3 25 | $784.5M | $1.0B | ||
| Q2 25 | $724.5M | $988.0M | ||
| Q1 25 | $695.4M | $906.0M | ||
| Q4 24 | $730.5M | $952.0M | ||
| Q3 24 | $702.5M | $948.0M | ||
| Q2 24 | $701.8M | $861.0M | ||
| Q1 24 | $659.2M | $763.0M |
净利润AMRXRIG
| Q4 25 | $35.1M | $25.0M | ||
| Q3 25 | $2.4M | $-1.9B | ||
| Q2 25 | $22.4M | $-938.0M | ||
| Q1 25 | $12.2M | $-79.0M | ||
| Q4 24 | $-31.1M | $7.0M | ||
| Q3 24 | $-156.0K | $-494.0M | ||
| Q2 24 | $6.0M | $-123.0M | ||
| Q1 24 | $-91.6M | $98.0M |
毛利率AMRXRIG
| Q4 25 | 36.5% | 42.0% | ||
| Q3 25 | 34.9% | 43.2% | ||
| Q2 25 | 39.5% | 39.4% | ||
| Q1 25 | 36.8% | 31.8% | ||
| Q4 24 | 36.0% | 39.2% | ||
| Q3 24 | 38.4% | 40.6% | ||
| Q2 24 | 35.6% | 38.0% | ||
| Q1 24 | 36.1% | 31.5% |
营业利润率AMRXRIG
| Q4 25 | 13.8% | 23.0% | ||
| Q3 25 | 9.0% | -163.1% | ||
| Q2 25 | 15.4% | -97.6% | ||
| Q1 25 | 14.4% | 7.1% | ||
| Q4 24 | 10.4% | 13.7% | ||
| Q3 24 | 12.6% | -51.2% | ||
| Q2 24 | 13.6% | -6.9% | ||
| Q1 24 | -1.6% | -0.4% |
净利率AMRXRIG
| Q4 25 | 4.3% | 2.4% | ||
| Q3 25 | 0.3% | -187.1% | ||
| Q2 25 | 3.1% | -94.9% | ||
| Q1 25 | 1.8% | -8.7% | ||
| Q4 24 | -4.3% | 0.7% | ||
| Q3 24 | -0.0% | -52.1% | ||
| Q2 24 | 0.9% | -14.3% | ||
| Q1 24 | -13.9% | 12.8% |
每股收益（稀释后）AMRXRIG
| Q4 25 | $0.10 | $0.13 | ||
| Q3 25 | $0.01 | $-2.00 | ||
| Q2 25 | $0.07 | $-1.06 | ||
| Q1 25 | $0.04 | $-0.11 | ||
| Q4 24 | $-0.10 | $-0.14 | ||
| Q3 24 | $0.00 | $-0.58 | ||
| Q2 24 | $0.02 | $-0.15 | ||
| Q1 24 | $-0.30 | $0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $620.0M |
| 总债务越低越好 | $2.6B | $5.2B |
| 股东权益账面价值 | $-70.8M | $8.1B |
| 总资产 | $3.7B | $15.6B |
| 负债/权益比越低杠杆越低 | — | 0.64× |
8季度趋势，按日历期对齐
现金及短期投资AMRXRIG
| Q4 25 | $282.0M | $620.0M | ||
| Q3 25 | $201.2M | $833.0M | ||
| Q2 25 | $71.5M | $377.0M | ||
| Q1 25 | $59.2M | $263.0M | ||
| Q4 24 | $110.6M | $560.0M | ||
| Q3 24 | $74.0M | $435.0M | ||
| Q2 24 | $43.8M | $475.0M | ||
| Q1 24 | $46.5M | $446.0M |
总债务AMRXRIG
| Q4 25 | $2.6B | $5.2B | ||
| Q3 25 | $2.6B | $4.8B | ||
| Q2 25 | $2.2B | $5.9B | ||
| Q1 25 | $2.2B | $5.9B | ||
| Q4 24 | $2.4B | $6.2B | ||
| Q3 24 | $2.4B | $6.5B | ||
| Q2 24 | $2.4B | $6.8B | ||
| Q1 24 | $2.4B | $6.8B |
股东权益AMRXRIG
| Q4 25 | $-70.8M | $8.1B | ||
| Q3 25 | $-109.5M | $8.1B | ||
| Q2 25 | $-112.1M | $9.4B | ||
| Q1 25 | $-131.7M | $10.2B | ||
| Q4 24 | $-109.3M | $10.3B | ||
| Q3 24 | $-93.4M | $10.2B | ||
| Q2 24 | $-57.5M | $10.7B | ||
| Q1 24 | $-63.7M | $10.5B |
总资产AMRXRIG
| Q4 25 | $3.7B | $15.6B | ||
| Q3 25 | $3.6B | $16.2B | ||
| Q2 25 | $3.4B | $17.8B | ||
| Q1 25 | $3.4B | $19.0B | ||
| Q4 24 | $3.5B | $19.4B | ||
| Q3 24 | $3.5B | $19.5B | ||
| Q2 24 | $3.5B | $20.3B | ||
| Q1 24 | $3.5B | $19.9B |
负债/权益比AMRXRIG
| Q4 25 | — | 0.64× | ||
| Q3 25 | — | 0.60× | ||
| Q2 25 | — | 0.63× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | — | 0.60× | ||
| Q3 24 | — | 0.64× | ||
| Q2 24 | — | 0.63× | ||
| Q1 24 | — | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $349.0M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $321.0M |
| 自由现金流率自由现金流/营收 | 13.3% | 30.8% |
| 资本支出强度资本支出/营收 | 2.7% | 2.7% |
| 现金转化率经营现金流/净利润 | 3.72× | 13.96× |
| 过去12个月自由现金流最近4个季度 | $269.9M | $626.0M |
8季度趋势，按日历期对齐
经营现金流AMRXRIG
| Q4 25 | $130.3M | $349.0M | ||
| Q3 25 | $118.5M | $246.0M | ||
| Q2 25 | $83.8M | $128.0M | ||
| Q1 25 | $7.4M | $26.0M | ||
| Q4 24 | $118.1M | $206.0M | ||
| Q3 24 | $141.8M | $194.0M | ||
| Q2 24 | $39.7M | $133.0M | ||
| Q1 24 | $-4.4M | $-86.0M |
自由现金流AMRXRIG
| Q4 25 | $108.5M | $321.0M | ||
| Q3 25 | $106.2M | $235.0M | ||
| Q2 25 | $61.0M | $104.0M | ||
| Q1 25 | $-5.8M | $-34.0M | ||
| Q4 24 | $102.9M | $177.0M | ||
| Q3 24 | $124.8M | $136.0M | ||
| Q2 24 | $29.0M | $49.0M | ||
| Q1 24 | $-13.6M | $-169.0M |
自由现金流率AMRXRIG
| Q4 25 | 13.3% | 30.8% | ||
| Q3 25 | 13.5% | 22.9% | ||
| Q2 25 | 8.4% | 10.5% | ||
| Q1 25 | -0.8% | -3.8% | ||
| Q4 24 | 14.1% | 18.6% | ||
| Q3 24 | 17.8% | 14.3% | ||
| Q2 24 | 4.1% | 5.7% | ||
| Q1 24 | -2.1% | -22.1% |
资本支出强度AMRXRIG
| Q4 25 | 2.7% | 2.7% | ||
| Q3 25 | 1.6% | 1.1% | ||
| Q2 25 | 3.2% | 2.4% | ||
| Q1 25 | 1.9% | 6.6% | ||
| Q4 24 | 2.1% | 3.0% | ||
| Q3 24 | 2.4% | 6.1% | ||
| Q2 24 | 1.5% | 9.8% | ||
| Q1 24 | 1.4% | 10.9% |
现金转化率AMRXRIG
| Q4 25 | 3.72× | 13.96× | ||
| Q3 25 | 50.00× | — | ||
| Q2 25 | 3.74× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | — | 29.43× | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.62× | — | ||
| Q1 24 | — | -0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
RIG
| Ultra Deepwater Floaters | $433.0M | 42% |
| BR | $236.0M | 23% |
| Other Geographical | $211.0M | 20% |
| Harsh Environment Floaters | $163.0M | 16% |
